57 Stars

Headquartered in London, 57 Stars operates as a global private equity and venture firm with a co-investment orientation that brings it into late-stage healthcare deals alongside lead investors. The firm has built a track record around scaling medical devices and health IT platforms, with a notable position in European diagnostics company Cirdan. While its mandate spans multiple sectors and geographies, medical devices, MedTech and healthcare software constitute meaningful pillars of its portfolio activity. The firm operates as a generalist with selective healthcare depth rather than a sector-pure specialist.

57 Stars concentrates on growth-stage opportunities, with typical commitments in the $5M to $25M range. Geographic reach is genuinely global, with investments deployed across Europe, North America and select emerging markets. The firm frequently acts as a co-investor on syndicate rounds, partnering with sector-specialist leads on diagnostics platforms, regulated medical device manufacturers, and software businesses serving healthcare providers. Deals tend to involve commercial-stage assets with established revenue traction rather than pre-clinical or early-development risk profiles.

For founders, 57 Stars represents institutional follow-on capital appropriate for scaling internationally validated products into new markets. The firm’s value-add is centered on capital provision and cross-border syndication rather than hands-on clinical or operational guidance. Founders should expect standard institutional diligence, board observation rights rather than full board seats in many cases, and an emphasis on portfolio companies that already have a defined commercial trajectory. The firm is best suited to growth-stage healthcare businesses seeking to extend geographic reach and looking for capital partners comfortable with cross-jurisdictional regulatory environments.